Health and Healthcare

Gilead Sciences : GILD

All Gilead Sciences Articles

732 Articles

Trey Thoelcke | Aug 10, 2012 at 9:51 AM EDT

Biotech: Dendreon and Regeneron Draw Short Interest

The short interest data is out from the July 31 settlement date and, with a couple of notable exceptions, short…

Jon C. Ogg | Aug 7, 2012 at 8:39 AM EDT

Top Analyst Upgrades and Downgrades (AMGN, AMT, AMAT, COH, DELL, FLEX, GILD, HPQ, KCG, LEAP, NTAP, SANM, SPLK, VE, VRTX, VVUS, WMT)

Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen from Wall St. research calls this Tuesday…

Jon C. Ogg | Aug 2, 2012 at 11:47 AM EDT

Gilead Options & New High In Stock Bring Hope For Further Upside

Gilead Sciences Inc. (NASDAQ: GILD) is seeing shares surge today on news that Bristol-Myers Squibb Co. (NYSE: BMY) has run…

Paul Ausick | Jul 26, 2012 at 4:04 PM EDT

24/7 Wall St. Closing Bell — July 26, 2012: Market Jumps on ECB President’s Vow

The three major US stock indexes opened higher this morning following European Central Bank president Mario Draghi’s promise to “do…

Jon C. Ogg | Jul 24, 2012 at 1:43 PM EDT

How ‘At-Risk’ Is Gilead’s HIV/AIDS Drug Dominance? (GILD, MRK, GSK)

GileadGilead Sciences, Inc. (NASDAQ: GILD) has a product chest that includes Atripla, Truvada, Viread, Complera/Eviplera, and Emtriva for the treatment…

Jon C. Ogg | Jul 3, 2012 at 7:35 AM EDT

GlobeImmune Files For IPO, Cancer & Hepatitis with Great Partnerships

GlobeImmune, Inc. is the latest biotech to file for an initial public offering. Financial terms were not disclosed but the…

Jon C. Ogg | Apr 18, 2012 at 8:23 AM EDT

Key Biotech Issues To Watch (XBI, ANIK, BCRX, CBST, DNDN, GILD, ILMN, TRGT)

Biotech is a sector which is often mixed with a hodge-podge of winners and losers based on news flow from…

Jon C. Ogg | Apr 4, 2012 at 1:28 PM EDT

Abbott’s Hep-C Pressures All Hep-C Rivals (ABT, RIGL, GILD, VRTX, IDIX)

News from Abbott Laboratories (NYSE: ABT) on its positive Phase II study results from two different interferon-free hepatitis C treatment…

Jon C. Ogg | Feb 25, 2012 at 7:31 AM EST

24/7 Wall St. Top Analyst Calls of the Week (BX, APO, CMA, DELL, DANG, EXM, FSLR, GILD, LVLT, ERIC, MAR, ORCL, SUN, VVUS, WBMD)

Jon OggEach weekend we review the many analyst calls we track during the week. Some turn out to be very…

Paul Ausick | Feb 22, 2012 at 4:07 PM EST

24/7 Wall St. Closing Bell (AAPL, DELL, MOS, GILD, DNDN, BAS, CYH, LOPE, RRC, CETV, CHS, DLTR, GRMN, NG, RRD, TOL, HSTM, FIRE, THLD, NFX, CELL)

US equities markets opened lower this morning following surprisingly weak manufacturing reports from Europe and China. Fitch Ratings’ downgrade of…

Jon C. Ogg | Feb 22, 2012 at 8:05 AM EST

Top Analyst Upgrades & Downgrades (ASX, AAPL, BX, BRCM, CIEN, CMA, DELL, DNDN, DANG, GILD, MDT, MOS, EDU, SPIL, TSM)

Jon OggThese are some of this Wednesday’s top analyst upgrades, downgrades, and initiations seen in Wall Street research calls. Advanced…

Paul Ausick | Feb 21, 2012 at 4:05 PM EST

24/7 Wall St. Closing Bell (ORCL, ITRI, CSX, ABB, GILD, BKS, BYD, CCO, CIE, DTG, HL, JAKK, M, MDT, PXD, SKS, WLK, THLD, CORT, GTXI, CHTP, WMT, WFT)

US markets opened higher this morning and traded higher for most of the day. The DJIA briefly rose above 13,000…

Jon C. Ogg | Feb 21, 2012 at 8:28 AM EST

Top Analyst Upgrades & Downgrades (ABB, ABG, BBVA, BGS, CSX, GILD, IMUC, INFY, ITRI, KLAC, LRCX, NEE, NSC, ORCL, WSH)

Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street research calls this Tuesday…

Paul Ausick | Feb 17, 2012 at 4:06 PM EST

24/7 Wall St. Closing Bell (CHK, WYN, CMCSA, RL, DELL, CEG, ENB, SPWR, HNZ, CPB, DMD, BDCO, CTIC, GILD, SCON)

US stocks opened mixed this morning, with the Nasdaq opening lower than both the DJIA and the S&P 500. The…

Paul Ausick | Feb 17, 2012 at 12:27 PM EST

Mid-day Movers (ACHN, RAIL, DMD, KONA, GILD)

At about noon ET today, two of the three major equity indexes remain solidly positive, with the DJIA up nearly…

1 … 42 43 44 45 46 … 49

Gilead Sciences : GILD

All Gilead Sciences Articles

Biotech: Dendreon and Regeneron Draw Short Interest

Top Analyst Upgrades and Downgrades (AMGN, AMT, AMAT, COH, DELL, FLEX, GILD, HPQ, KCG, LEAP, NTAP, SANM, SPLK, VE, VRTX, VVUS, WMT)

Gilead Options & New High In Stock Bring Hope For Further Upside

24/7 Wall St. Closing Bell — July 26, 2012: Market Jumps on ECB President’s Vow

How ‘At-Risk’ Is Gilead’s HIV/AIDS Drug Dominance? (GILD, MRK, GSK)

GlobeImmune Files For IPO, Cancer & Hepatitis with Great Partnerships

Key Biotech Issues To Watch (XBI, ANIK, BCRX, CBST, DNDN, GILD, ILMN, TRGT)

Abbott’s Hep-C Pressures All Hep-C Rivals (ABT, RIGL, GILD, VRTX, IDIX)

24/7 Wall St. Top Analyst Calls of the Week (BX, APO, CMA, DELL, DANG, EXM, FSLR, GILD, LVLT, ERIC, MAR, ORCL, SUN, VVUS, WBMD)

24/7 Wall St. Closing Bell (AAPL, DELL, MOS, GILD, DNDN, BAS, CYH, LOPE, RRC, CETV, CHS, DLTR, GRMN, NG, RRD, TOL, HSTM, FIRE, THLD, NFX, CELL)

Top Analyst Upgrades & Downgrades (ASX, AAPL, BX, BRCM, CIEN, CMA, DELL, DNDN, DANG, GILD, MDT, MOS, EDU, SPIL, TSM)

24/7 Wall St. Closing Bell (ORCL, ITRI, CSX, ABB, GILD, BKS, BYD, CCO, CIE, DTG, HL, JAKK, M, MDT, PXD, SKS, WLK, THLD, CORT, GTXI, CHTP, WMT, WFT)

Top Analyst Upgrades & Downgrades (ABB, ABG, BBVA, BGS, CSX, GILD, IMUC, INFY, ITRI, KLAC, LRCX, NEE, NSC, ORCL, WSH)

24/7 Wall St. Closing Bell (CHK, WYN, CMCSA, RL, DELL, CEG, ENB, SPWR, HNZ, CPB, DMD, BDCO, CTIC, GILD, SCON)

Mid-day Movers (ACHN, RAIL, DMD, KONA, GILD)

‘You’re Gonna Go Into Retirement Broke and Wait on Mom to Die’: Dave Ramsey’s Reality Check for a Caller Eyeing His Inheritance

“You Don’t Want to Pass the Burden of Investments Down to Your Daughter”: Suze Orman’s Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings

EEM’s 0.69% Fee Quietly Costs You $690 a Year, but Your Cheaper Alternative Charges $90

'You're Gonna Go Into Retirement Broke and Wait on Mom to Die': Dave Ramsey's Reality Check for a Caller Eyeing His Inheritance

"You Don't Want to Pass the Burden of Investments Down to Your Daughter": Suze Orman's Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings

‘You’re Gonna Go Into Retirement Broke and Wait on Mom to Die’: Dave Ramsey’s Reality Check for a Caller Eyeing His Inheritance

“You Don’t Want to Pass the Burden of Investments Down to Your Daughter”: Suze Orman’s Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings

Gilead Sciences : GILD

All Gilead Sciences Articles

Biotech: Dendreon and Regeneron Draw Short Interest

Top Analyst Upgrades and Downgrades (AMGN, AMT, AMAT, COH, DELL, FLEX, GILD, HPQ, KCG, LEAP, NTAP, SANM, SPLK, VE, VRTX, VVUS, WMT)

Gilead Options & New High In Stock Bring Hope For Further Upside

24/7 Wall St. Closing Bell — July 26, 2012: Market Jumps on ECB President’s Vow

How ‘At-Risk’ Is Gilead’s HIV/AIDS Drug Dominance? (GILD, MRK, GSK)

GlobeImmune Files For IPO, Cancer & Hepatitis with Great Partnerships

Key Biotech Issues To Watch (XBI, ANIK, BCRX, CBST, DNDN, GILD, ILMN, TRGT)

Abbott’s Hep-C Pressures All Hep-C Rivals (ABT, RIGL, GILD, VRTX, IDIX)

24/7 Wall St. Top Analyst Calls of the Week (BX, APO, CMA, DELL, DANG, EXM, FSLR, GILD, LVLT, ERIC, MAR, ORCL, SUN, VVUS, WBMD)

24/7 Wall St. Closing Bell (AAPL, DELL, MOS, GILD, DNDN, BAS, CYH, LOPE, RRC, CETV, CHS, DLTR, GRMN, NG, RRD, TOL, HSTM, FIRE, THLD, NFX, CELL)

Top Analyst Upgrades & Downgrades (ASX, AAPL, BX, BRCM, CIEN, CMA, DELL, DNDN, DANG, GILD, MDT, MOS, EDU, SPIL, TSM)

24/7 Wall St. Closing Bell (ORCL, ITRI, CSX, ABB, GILD, BKS, BYD, CCO, CIE, DTG, HL, JAKK, M, MDT, PXD, SKS, WLK, THLD, CORT, GTXI, CHTP, WMT, WFT)

Top Analyst Upgrades & Downgrades (ABB, ABG, BBVA, BGS, CSX, GILD, IMUC, INFY, ITRI, KLAC, LRCX, NEE, NSC, ORCL, WSH)

24/7 Wall St. Closing Bell (CHK, WYN, CMCSA, RL, DELL, CEG, ENB, SPWR, HNZ, CPB, DMD, BDCO, CTIC, GILD, SCON)

Mid-day Movers (ACHN, RAIL, DMD, KONA, GILD)

‘You’re Gonna Go Into Retirement Broke and Wait on Mom to Die’: Dave Ramsey’s Reality Check for a Caller Eyeing His Inheritance

“You Don’t Want to Pass the Burden of Investments Down to Your Daughter”: Suze Orman’s Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings

EEM’s 0.69% Fee Quietly Costs You $690 a Year, but Your Cheaper Alternative Charges $90

Featured Reads

'You're Gonna Go Into Retirement Broke and Wait on Mom to Die': Dave Ramsey's Reality Check for a Caller Eyeing His Inheritance

"You Don't Want to Pass the Burden of Investments Down to Your Daughter": Suze Orman's Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings